Skip to search formSkip to main contentSkip to account menu

VX 497

Known as: VX-497 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Merimepodib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C.
Inhibition of inosine monophosphate dehydrogenase (IMPDH) is one of several proposed mechanisms of action for ribavirin (RBV), a… 
Highly Cited
2001
Highly Cited
2001
VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent.
Inosine monophosphate dehydrogenase (IMPDH) is an essential rate-limiting enzyme in the purine metabolic pathway, catalyzing the… 
2001
2001
The novel IMPDH inhibitor VX-497 prolongs skin graft survival and improves graft versus host disease in mice.
VX-497 is the first inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor generated in a structure-based drug design program… 
2001
2001
Characterisation of interferon alfa-2a and pegylated interferon alfa-2A in combination with ribavirin, mycophenolic acid or VX-497 as inhibitors of HCV replicon replication
1999
1999
THE NOVEL IMPDH INHIBITOR VX-497 PROLONGS SKIN GRAFT SURVIVAL AND IMPROVES GVHD IN MOUSE
1999
1999
The IMPDH inhibitor VX-497 is the first rationally synthesized immunosuppressant to prolong allograft survival
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)